Holen Sie sich die Stockscreener-App
18.38
2.91%
0.52
Handel nachbörslich:
18.26
-0.12
-0.65%
Schlusskurs vom Vortag:
$17.86
Offen:
$17.5
24-Stunden-Volumen:
2.46M
Relative Volume:
0.51
Marktkapitalisierung:
$6.43B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-277.02M
KGV:
-19.70
EPS:
-0.9328
Netto-Cashflow:
$-91.36M
1W Leistung:
-0.16%
1M Leistung:
-5.74%
6M Leistung:
+53.17%
1J Leistung:
+1,071%
1-Tages-Spanne:
$17.30
$18.46
1-Wochen-Bereich:
$17.30
$19.22
52-Wochen-Spanne:
$1.3301
$24.28
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
18.38 | 6.50B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - simplywall.st
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - marketbeat.com
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
HC Wainwright Has Negative Estimate for Erasca Q3 Earnings - marketbeat.com
BofA Adjusts Price Target on Erasca to $20 From $18 - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
Guggenheim raises Erasca stock price target to $21 on pipeline progress - Investing.com South Africa
Erasca Awards 1.3 Million Stock Options to New President of R&D - Kalkine Media
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.82, Implies 25% Upside - TradingView
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside - TradingView
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Erasca (NASDAQ:ERAS) Given New $22.00 Price Target at HC Wainwright - marketbeat.com
H.C. Wainwright raises Erasca stock price target on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Erasca stock price target on trial progress - Investing.com
ERAS Maintained by HC Wainwright & Co. -- Price Target Raised to $22 - GuruFocus
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS - marketbeat.com
Erasca (NASDAQ:ERAS) Announces Earnings Results, Misses Expectations By $0.03 EPS - marketbeat.com
Erasca Q2 EPS of $(0.14) misses $(0.11) estimate on R&D spend - scanx.trade
Earnings Flash (ERAS) Erasca Posts Q2 Loss $0.14 per Share, vs. FactSet Est of $0.11 Loss - marketscreener.com
Erasca, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ERAS: ERAS-0015 delivers strong efficacy and safety in RAS-mutant cancers, advancing toward pivotal trials - TradingView
Erasca Reports Second Quarter 2026 Business Updates and Financial Results - The Manila Times
Erasca, Inc. 2Q 2026: Net income $(44.1M), EPS $(0.14) — 10-Q Summary - TradingView
Erasca (ERAS) boosts cash by $836M while advancing RAS oncology pipeline - Stock Titan
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
ERAS DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
812,876 Shares in Erasca, Inc. $ERAS Acquired by Assenagon Asset Management S.A. - marketbeat.com
Erasca appoints Charles Fuchs as R&D president By Investing.com - Investing.com India
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - moomoo.com
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Eras - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - 巴士的報
Erasca appoints Charles Fuchs as R&D president - Investing.com
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline - PR Newswire
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D - The Manila Times
Erasca, Inc. Announces Appointment of Charles S. Fuchs as President of Research and Development, Effective on August 10, 2026 - marketscreener.com
California State Teachers Retirement System Grows Position in Erasca, Inc. $ERAS - marketbeat.com
Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Seek L - The National Law Review
ERAS DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Erasca, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ERAS DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts - The National Law Review
ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc.ERAS - ACCESS Newswire
ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure ... - Caledonian Record
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):